ADVM — Adverum Biotechnologies Income Statement
0.000.00%
- $142.39m
- -$50.94m
- $3.60m
- 16
- 39
- 51
- 28
Annual income statement for Adverum Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.25 | 0 | 7.5 | 0 | 3.6 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 68.8 | 118 | 154 | 157 | 128 |
Operating Profit | -68.5 | -118 | -146 | -157 | -124 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -64.5 | -116 | -146 | -154 | -118 |
Provision for Income Taxes | |||||
Net Income After Taxes | -64.5 | -118 | -146 | -155 | -117 |
Net Income Before Extraordinary Items | |||||
Net Income | -64.5 | -118 | -146 | -155 | -117 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -64.5 | -118 | -146 | -155 | -117 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -10.1 | -13.8 | -14.7 | -15.4 | -11.6 |